Back to today’s briefing

Story perspectives

Hims & Hers Revenue Soars 95%, Shares Plunge 20%

2/25/2025

50 4

Summary

Hims & Hers Revenue Surge

Hims & Hers Health celebrated a remarkable 95% surge in revenue, reaching $481 million in Q4 2024. However, shares plummeted nearly 20% as concerns over shrinking gross margins and the FDA's decision to remove semaglutide from its shortage list weighed heavily. Looking ahead, the company aims to pivot away from compounded weight-loss drugs, targeting $725 million in revenue from alternative offerings in 2025.

Summary

Hims & Hers Growth Prospects

Hims & Hers Health celebrated a remarkable Q4 2024, boasting revenues of $481.1 million—a staggering 95.1% surge from last year. However, shares plummeted 16% amid disappointing customer growth and EBITDA results. Looking ahead, the company projects a promising $2.35 billion in revenue for 2025, signaling robust potential in the telehealth arena.

History

Historical Context

Hims & Hers Health's revenue surge echoes the rapid growth of telehealth during the COVID-19 pandemic. Just as healthcare companies adapted to digital demands then, Hims & Hers now pivots from compounded drugs, reflecting ongoing shifts in consumer needs and regulatory challenges faced in the healthcare sector.

1 of 3

Hims & Hers Revenue Surge

Hims & Hers Health celebrated a remarkable 95% surge in revenue, reaching $481 million in Q4 2024. However, shares plummeted nearly 20% as concerns over shrinking gross margins and the FDA's decision to remove semaglutide from its shortage list weighed heavily. Looking ahead, the company aims to pivot away from compounded weight-loss drugs, targeting $725 million in revenue from alternative offerings in 2025.

1 / 3